Jounce Therapeutics Reports Second Quarter 2020 Financial Results
- Completed enrollment of Phase 2 EMERGE trial for the interim analysis of efficacy and biomarker data in early 2021 - - On track to initiate Phase 2 SELECT trial and Phase 1 trial for JTX-8064 in 2020 - - Ended the quarter with $127.2 million in cash, …